TrialThe Lancet. Oncology2013

Docetaxel and atrasentan versus docetaxel and placebo for men with advanced castration-resistant prostate cancer (SWOG S0421): a randomised phase 3 trial.

David I Quinn et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.